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Abstract A Bacillus subtilis strain deficient in seven extra-
cellular proteases was used to produce human mast cell chymase 
and is a viable expression system for serine proteases and other 
classes of proteins. Chymase is produced at 0.3-0.5 mg/1 and is 
purified by three chromatography steps. Two crystal forms of 
PMSF-treated chymase were optimized. The first is C2 with 
a = 47.94 A, b = 85.23 A, c = 174.18 A, P = 96.74°, and diffracts 
to at least 2.1 A, while the second is P212121, with cell 
dimensions a = 43.93 A, 6 = 58.16 A, and c = 86.09 A, and a 
diffraction limit of approximately 1.9 A. The first crystal form 
has either three or four molecules/asymmetric unit, while the 
second has one molecule/asymmetric unit. 
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1. Introduction 
H u m a n chymase is a mast cell serine protease with chymo-
trypsin-like specificity [1,2]. The enzyme is initially synthesized 
as an inactive precursor but is ultimately stored in, and re-
leased from, the secretory granules of mast cells as a mature 
enzyme [3-5]. Processing of the precursor appears to involve 
removal of a signal peptide followed by D P P 1-mediated re-
moval of the Gly-Glu propeptide in a heparin-dependent re-
action [6,7]. H u m a n chymase has been implicated in a variety 
of physiological and pathological processes including vasoac-
tive peptide processing [8,9], tissue remodeling [10], activation 
of p ro IL- ip [11], and release of latent growth factors from the 
extracellular matrix [12]. While the parent chymotrypsin 
shows a relaxed substrate specificity, with clear preferences 
observed only for the PI substrate position, chymase is a 
much more selective enzyme. Specificity for Phe, Tyr, or 
Trp at PI remains, but is then limited by strict requirements 
for the extended substrate-binding site. For example, human 
chymase activates angiotensin I to angiotensin II by cleavage 
of a Phe-His bond, but does not degrade angiotensin II by 
clipping a Tyr-I le bond, as do chymotrypsin, and chymases 
from other species [9]. To date, only one chymase gene has 
been identified in humans [13], although a Cys-to-Ser varia-
tion at position seven of the mature enzyme has been reported 
[14]. This is the first report of crystallization of human chym-
ase. An atomic resolution structure of human mast cell chym-
ase will provide useful information for understanding this 
enzyme's substrate specificity requirements and may shed light 
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on the details of activation by DPP1 , and the stabilizing role 
of heparin within the mast cell granule. 
Production of milligram quantities of pure chymase was a 
prerequisite for the structural studies. Although a variety of 
expression systems have proven useful for serine proteases, 
many are unsuitable for one reason or another. For example, 
Escherichia coli can produce serine proteases to high yield, but 
many are then found inextricably complexed with the peri-
plasmic inhibitor, ecotin [15,16]. Other reported expression 
systems for human chymase involve substantial downstream 
processing to recover limited amounts of active enzyme, e.g. 
refolding and proteolytic processing of an insoluble fusion 
protein [17] or proteolytic activation of secreted prochymase 
with cell extracts [6] or DPPI [7]. The B. subtilis system de-
scribed herein yields mature chymase, ideally suited for crys-
tallization because of the lack of glycosylation. B. subtilis has 
been successful at producing other serine proteases (B.F.S., 
unpublished results), and is a heretofore untapped resource 
as an expression system. 
2. Methods and results 
2.1. Expression 
E. coli XL-2 Blue {recAl endAl gyrA96 thi-1 hsdR17 supE44 
relAl lac [¥' proAB lad-'>ZAM15 TnlO (Tetr) Amy Cam1]} (Strata-
gene) or MM294 (endAl thi-1 hsdRll supE44) [18] were used as hosts 
for the vector constructions. Bacteria were transformed and plasmid 
DNA was purified as described elsewhere (B.F.S., manuscript in prep-
aration). 
B. subtilis WB751 (trp Aisp-1 AnprA AaprE Aepr Abpf Ampr-
Cam1 AnprB-Ery1 Avpr), a strain deficient in seven extracellular pro-
teases and one intracellular protease, was used for the production of 
human mast cell chymase C7S. This strain was constructed by deleting 
the vpr gene [19] from B. subtilis WB600 (trp Aisp-1 AnprA AaprE -
Aepr Abpf Ampr-Cam1 AnprB-Ery') [20]. To accomplish this, two 
~ 1.2 kb PCR fragments, corresponding to either a 5'- or 3'-portion 
of the vpr gene, were generated by Taq polymerase (Perkin-Elmer) 
with the primers GATATCCAGAATTCCACAAACTCTATCTA-
TATTTTGTATACGAA and GCCGTTCGGATCCTCAATCACT-
TATGAGGTAACAGCGACAACGCCTTCTGACATGGC, or the 
primers GATACGTGGATCCTTAAGCCTGATATTTCCGCGCC-
AG and GTATCCCTGCAGGAGTCCTCGTATGAAGCTGTTCG-
G (ABI 394 DNA/RNA Synthesizer, Perkin-Elmer), respectively, us-
ing chromosomal DNA from B. subtilis BG2036(A«/>M AaprE) (a 
generous gift from Genencor International, Inc.) as a template. The 
two PCR generated fragments (EcoKl-BamHi and BamHl-Psti) were 
inserted in pBluescript SK+ (Stratagene) with the kanamycin gene 
( = 1.4 kb EcoRl-Sall fragment) from pJM114 [21]. The deletion of 
amino acids 212-A5\ of the Vpr protease and the introduction of stop 
codons in all three frames after amino acid 271 were verified by DNA 
sequencing (ABI 373A DNA Sequencer, Perkin-Elmer). The resultant 
vector was used to transform B. subtilis WB600 cells. Clones with the 
vector integrated into the chromosome were selected by plating on 
Luria agar plates with 10 |ig/ml kanamycin. Integration at the vpr 
gene locus was determined by screening the chromosomal DNA of 
the transformants using PCR primers that flank the vpr gene. Positive 
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Fig. 1. A schematic representation of the expression cassette used to produce human mast cell chymase C7S in B. subtilis. Expression is driven 
by the B. subtilis aprE promoter [28] shown as the thick black arrow. The chymase gene is represented by the white box and downstream is the 
transcription terminator from the B. amyloliquefaciens aprE gene [29] shown as a thick black hne. The DNA and protein sequence of the aprE 
signal sequence (underlined) fused to the mature chymase gene is shown below the schematic figure. Amino acids 9-30 of the signal sequence 
are derived from the B. amyloliquefaciens aprE gene. 
clones were grown in Luria broth for 6-14 h then used to inoculate 
another 15 ml of fresh Luria medium (no kanamycin selection). The 
re-inoculation process was repeated for up to 2 weeks. Colonies that 
eventually lost the kanamycin resistance were screened by PCR in 
order to select clones where the native vpr gene was replaced with 
the deleted version. 
A DNA fragment of the human chymase gene [5] was generated by 
PCR with the primers GGGAATATTATCGGGGGTACCGAATG-
CAAGCCACATTCTAGACCCTACA and GATCGTTAATTAAT-
TTGCCTGCAGGATCTGGTTGATCCAGGG using a cDNA li-
brary constructed from ascites tissue as a template [22]. The ~700 
bp Xbal-Pacl gene fragment was ligated into the i toHIi and Pad 
sites of the B. subtilis expression vector pBNppt (B.F.S., manuscript in 
preparation) using a BssHll-Xbal synthetic DNA linker. This linker 
also substitutes the cysteine residue with serine at amino acid seven of 
the mature chymase since it was discovered that native human chym-
ase with a free thiol group is not effectively produced in prokaryotic 
systems (J.M.C. and B.F.S., unpublished results). The entire sequence 
of the gene was verified by sequencing both DNA strands. A schem-
atic representation of the expression-secretion construction is shown 
in Fig. 1. 
2.2. Fermentation and purification 
Chymase-producing B. subtilis was grown in 4 1 of baffled shake 
flasks (Bellco) at 37°C, 270 r.p.m. A rich medium [23] was used for 
production and consisted of 3% (w/v) tryptone (Difco), 2% (w/v) yeast 
extract (Difco), 3% (w/v) glucose, 150 mM potassium phosphate, pH 
7.4, 10.0 u.g/ml neomycin. An inoculum (1 1) was grown overnight and 
r 
i 
t 
Heparin 
Pool 
S Sepharose 
Pool S100 
Pool 
Fig. 2. A silver-stained 4-20% SDS-PAGE gel showing chymase at various purification steps. Chymase is the major protein band seen in the 
lane containing the pool from the S-100 chromatography step. 
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150 ml was used to seed each of six flasks containing 1 1 of media. 
Cultures were grown for 6 h and harvested by centrifugation at 7200 
r.c.f. The supernatant was filtered by passage through a 0.2 urn Sar-
tobran-PH capsule filter (Sartorius, Edgewood, NY). Approximately 
0.3-0.5 mg of purified chymase was produced per liter of fermentation 
broth, as determined by activity. 
Chymase activity was measured by hydrolysis of suc-Val-Pro-Phe-
SBzl (Bachem) with 4,4'-dithiodipyridine (Sigma), in assay buffer (30 
mM Tris-HCl, 1.0 M NaCl, 0.05% (v/v) Tween 20, 10% (v/v) DMSO, 
pH 8.0). Beads of Heparin Sepharose CL-6B (Pharmacia, Piscataway, 
NJ) were added to the filtered harvest supernatant at a ratio of up to 
0.5 1 of harvest/ml resin and suspended with mild agitation for 1 h. 
The beads were collected on a 0.8 urn filter (Nalgene), resuspended in 
20 mM MES, 150 mM NaCl, pH 5.5, and packed into a 5-cm-diam-
eter column. Chymase was eluted from the column using a gradient of 
0.52-2 M NaCl over five column volumes in 20 mM MES, pH 5.5. 
Fractions which tested positive for chymase activity were pooled, and 
diluted to a conductivity of 25 mS/cm with 20 mM MES, pH 5.5. The 
diluted chymase pool was applied to a SP-Sepharose FF column 
(1.6x10 cm, Pharmacia) equilibrated in 20 mM MES, 0.4 M NaCl, 
pH 5.5. Chymase was eluted from the column using a gradient of 0.4-
1 M NaCl over 10 column volumes in 20 mM MES, pH 5.5. Chym-
ase-rich fractions eluted in a peak centered around 0.7 M NaCl, and 
were assessed for purity by SDS-PAGE and pooled. The SP-Sephar-
ose FF chymase pool was applied to a Sephacryl S-100 HR (2.6x92 
cm, Pharmacia) column equilibrated with 20 mM MES, pH 5.5, with 
at least 0.4 M NaCl used to prevent background binding. Fractions 
that tested positive for chymase activity were assessed for purity by 
SDS-PAGE and pooled (Fig. 2). The identity of chymase was con-
firmed by Western blot analysis and by N-terminal sequencing of the 
first 12 residues (data not shown). The S-100 chymase pool was con-
centrated using a Collodion vacuum dialysis unit (Schleicher and 
Schuell, Keene, NH) fitted with a 10 kDa membrane. After concen-
trating to dryness, the chymase was reconstituted with 20 mM MES, 
pH 5.5, to a concentration greater than 5 g/1 (0.2 mM). An aliquot of 
200 mM phenylmethylsulfonylfluoride (PMSF) in dimethylsulfoxide 
(DMSO) was added to the concentrate to at most 5% (v/v) DMSO 
in the final solution. Approximately 40-fold stoichiometric excess of 
PMSF to chymase was used. 
2.3. Crystallization 
PMSF-treated chymase, at a concentration of approximately 5 mg/ 
ml, was subjected to hanging drop vapor-diffusion [24] crystallization 
experiments using factorial screening [25] kits (Hampton Research, 
Laguna Hills, CA). Preliminary crystals were obtained in a variety 
of polyethylene glycol (PEG) and PEG-monomethyl ether (MME) 
conditions. The pH of these conditions varied from 4.6 to 8.5, and 
salts such as ammonium sulfate, sodium chloride and sodium acetate 
also appear to facilitate crystallization. Two crystal forms were opti-
mized. The first, from 20 to 30%o PEG MME 2000, 0.1 M sodium 
acetate, pH 4.6, with 0.2 M ammonium sulfate was characterized and 
found to be space group C2. The cell constants are a = 47.94 A, 
6 = 85.23 A, c= 174.18 A, P = 96.74°. There appears to be either three 
or four molecules in the asymmetric unit, which corresponds to Mat-
thews' coefficients [26] of 2.5 A3/Da and 1.9 A3/Da, respectively. 
These crystals diffract to at least 2.1 A using an Raxis IV image plate 
system (MSC, The Woodlands, TX), with a Rigaku generator pow-
ered at 55 kVx90 mA, and have a useable X-ray lifetime of approx-
imately 15-24 h. The second crystal form is obtained from 20 PEG 
4000, 20% 2-propanol, 0.1 M sodium citrate, pH 5.6. These crystals 
were found to be of an orthorhombic habit, space group P2J2121, 
with cell dimensions a = 43.93 A, 6 = 58.16 A, and c= 86.09 A. The 
Matthews' coefficient is 2.3 A3/Da for one molecule in the asymmetric 
unit. The crystals diffract to approximately 1.9 A, and are not unusu-
ally sensitive to X-ray damage. The second crystal form provides a 
better opportunity for structure determination by molecular replace-
ment. To this end, search models have been constructed from a ho-
mology model of human chymase, derived, in part, from the related 
rat mast cell protease II structure (pdb: 3RP2, [27]; 60% identity). 
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